指南与共识介入腹部DSAPET

ACR-ABS-ACNM-ARS-SIR-SNMMI肝脏恶性肿瘤放射性栓塞实践参数

ACR-ABS-ACNM-ARS-SIR-SNMMI Practice Parameter for Radioembolization of Liver Malignancies.
指南 / 共识 · Am J Clin Oncol · 2025-09-03

该实践参数由ACR、ABS、ACNM、ARS、SIR和SNMMI协作修订,总结钇放射性栓塞治疗肝脏的循证指南,涵盖医师资质、适应证、禁忌证、操作流程、安全处理和监管要求,旨在为两种现有放射性栓塞装置提供安全有效治疗的框架。

要点

  • 多学科协作修订的实践参数,涵盖医师资质、适应证、禁忌证及操作流程。
  • 提供两种现有放射性栓塞装置给药的安全实践框架与监管要求。
  • 不定义最佳治疗患者,需多学科审查后个体化决定。

核心结论

  • 钇-90放射性栓塞治疗肝脏在原发性和转移性肝癌中作用日益增长,本实践参数旨在帮助各相关专科临床医生优化这些操作的有效性和安全性。

研究设计与样本

  • 由ACR介入与心血管放射学委员会、核医学与分子影像委员会及放射肿瘤学委员会的相关实践参数委员会,与ABS、ACNM、ARS、SIR和SNMMI协作,按ACR网站所述「ACR实践参数与技术标准制定流程」修订的实践参数。

诊断标准与关键数值

  • 讨论参与该治疗的医师资质、基本适应证、禁忌证、操作前检查、安全处理和选择性内放射治疗给药的监管要求。
  • 旨在为两种现有放射性栓塞装置的给药提供当前最佳实践框架。

临床应用与阅片要点

  • 本文件不定义哪些患者最适合这些治疗,这最好在多学科审查后针对个体患者决定。
  • 一致且循证的治疗方法将使所有接受该治疗的患者获益。

局限性

  • 本综述并非对肝脏放疗的全面讨论,而是旨在为安全有效的治疗提供参数。
  • 本文件的目标不是定义哪些患者最适合这些治疗,因为这最好在多学科审查后针对个体患者决定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The practice parameter was revised collaboratively by the American College of Radiology (ACR), the American Brachytherapy Society (ABS), the American College of Nuclear Medicine (ACNM), the American Radium Society (ARS), the Society of Interventional Radiology (SIR), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). This document summarizes current evidence-based guidelines for the administration of Yttrium radioembolic therapy to the liver, including training requirements, evidence-based guidelines for administration, and safe practice for administration.

METHODS: This practice parameter was revised according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website ( https://www.acr.org/ClinicalResources/Practice-Parameters-and-Technical-Standards ) by the Committee on Practice Parameters-Interventional and Cardiovascular Radiology of the ACR Commission on Interventional and Cardiovascular, Committee on Practice Parameters and Technical Standards-Nuclear Medicine and Molecular Imaging of the ACR Commission on Nuclear Medicine and Molecular Imaging and the Committee on Practice Parameters-Radiation Oncology of the ACR Commission on Radiation Oncology in collaboration with the ABS, the ACNM, the ARS, the SIR, and the SNMMI.

RESULTS: This review seeks not to be a comprehensive discussion of radiotherapy to the liver, but rather, seeks to provide a parameter for safe and effective therapy. We discuss the qualifications of physicians involved in this therapy, basic indications, contraindications, procedural work-up, safe-handling, and regulatory requirement for the administration of selective internal radiation therapy to patients that are likely to benefit. The goal of this document is not to define which patients are best treated by these therapies, as this is best determined for individual patients after multidisciplinary review. A consistent and evidence-based approach to therapy, however, would benefit all patients who are offered this therapy. This document seeks to provide a framework for current best practices for the administration of the 2 currently available radioembolization devices.

CONCLUSIONS: As Yttrium-90 radiotherapy to the liver occupies a growing role in the treatment of primary and metastatic liver cancer, this review seeks to assist clinicians of all involved specialties to optimize the efficacy and safety of these procedures.

来源:Am J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Johnson T, Spieler BO, Toskich BB, et al. ACR-ABS-ACNM-ARS-SIR-SNMMI Practice Parameter for Radioembolization of Liver Malignancies. Am J Clin Oncol. 2025. PMID: 40899409. doi:10.1097/COC.0000000000001234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。